Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
This head-to-head study tracked real-world data from 58,336 Medicare patients treated with either semaglutide or dulaglutide
Efficacy of probiotics in irritable bowel syndrome: Systematic review and meta-analysis
- Nearly one-third achieved both histologic endpoints - Mean body weight reduction: 10.5% with semaglutide vs 2.0% with placebo - Significant improvements in cardiometabolic parameters, including HbA1c, CRP, and liver stiffness - Side effects: Gastrointestinal (obvious), and overall safety was consistent with previous studies of semaglutide
By purchasing, you confirm you are a qualified researcher and assume full legal responsibility for compliance with all applicable laws in your jurisdiction
US$ 26.77
US$ 27.43
US$ 21.52
US$ 28.12
US$ 27.47
US$ 29.50
US$ 28.44
US$ 26.40
US$ 25.78
US$ 20.85
